Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Commentary

Abstract

Get full access to this article

View all access options for this article.

References

Montalban

. Review of methodological issues of clinical trials in multiple sclerosis. J Neurol Sci 2011; 311(Suppl. 1): S35–S42.

Meinert

. Clinical trials design, conduct and analysis. 2nd ed. New York: Oxford University Press, 2012.

IFNB Multiple Sclerosis Study Group. Interferon-1b is effective in relapsing–remitting multiple sclerosis. I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–661.

Goodin

Reder

Ebers

. Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology 2012; 78: 1315–1322.

Edan

Kappos

Montalbán

., for the BENEFIT Study Group. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry. [Epub ahead of print; 11 November 2013. DOI: 10.1136/jnnp-2013-306222].

Cohen

Barkhof

Comi

.; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.

Zajicek

Ball

Wright

.; CUPID investigator group. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): A randomised, placebo-controlled trial. Lancet Neurol 2013; 12: 857–865.

Chataway

Schuerer

Alsanousi

. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial. Lancet. [Epub before print 19 March 2014. DOI: 10.1016/S0140-6736(13)62242-4].

Multiple Sclerosis - secondary progressive multi-arm randomisation trial. http://www.ms-smart.org (accessed 2 June 2014).